Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.
Mei M, Tsai NC, Palmer J, Armenian S, Chen R, Rosen S, Forman S, Popplewell L, Kwak L, Martin P, Maddocks K, Bond D, Herrera AF.
Mei M, et al. Among authors: chen r.
Clin Lymphoma Myeloma Leuk. 2024 Aug;24(8):537-542. doi: 10.1016/j.clml.2024.03.013. Epub 2024 Apr 10.
Clin Lymphoma Myeloma Leuk. 2024.
PMID: 38693037
Clinical Trial.